Structure Therapeutics (NASDAQ:GPCR) Shares Up 5.2% - Here's Why

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) traded up 5.2% during trading on Tuesday . The company traded as high as $24.50 and last traded at $24.85. 25,373 shares changed hands during trading, a decline of 97% from the average session volume of 909,218 shares. The stock had previously closed at $23.62.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on GPCR shares. Citigroup started coverage on Structure Therapeutics in a research report on Friday. They issued a "buy" rating and a $60.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price target on shares of Structure Therapeutics in a research report on Tuesday, April 22nd. Stifel Nicolaus started coverage on shares of Structure Therapeutics in a report on Wednesday, January 8th. They set a "buy" rating and a $50.00 target price on the stock. Finally, William Blair assumed coverage on Structure Therapeutics in a research report on Friday, February 28th. They issued an "outperform" rating on the stock. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics has an average rating of "Buy" and an average target price of $78.63.

Structure Therapeutics Stock Up 1.7 %

The firm has a market cap of $1.59 billion, a P/E ratio of -37.85 and a beta of -1.35. The business's 50 day moving average is $20.40 and its 200-day moving average is $27.52.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01. As a group, equities analysts predict that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. ANTIPODES PARTNERS Ltd increased its holdings in shares of Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after acquiring an additional 553 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock worth $31,000 after purchasing an additional 1,122 shares during the period. GF Fund Management CO. LTD. bought a new position in shares of Structure Therapeutics in the 4th quarter worth about $34,000. FNY Investment Advisers LLC acquired a new position in shares of Structure Therapeutics in the 4th quarter valued at about $40,000. Finally, Virtus ETF Advisers LLC grew its position in shares of Structure Therapeutics by 25.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock valued at $61,000 after buying an additional 455 shares during the last quarter. Institutional investors own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.